Clinical trial Recruiting at 3 sites Phase 2 Interventional Ages 18 and up

Tegoprazan vs Lansoprazole for Healing Bleeding Peptic Ulcers

Official title: A Double-Blind, Double-Dummy, Randomized Controlled Trial Comparing 14-Day Tegoprazan Versus Lansoprazole Therapy for Endoscopic Ulcer Healing in Patients With Bleeding Peptic Ulcers

Run by Universitas Indonesia · NCT07708545 · Data updated 2026-11-12

This trial tests whether tegoprazan heals bleeding peptic ulcers faster than lansoprazole over 14 days in adults with upper GI bleeding in Indonesia.

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment162 (estimated)
SponsorUniversitas Indonesia
Academic / other
Drugs / interventionschemotherapy
Locations3 sites (Tangerang, Banten and 2 other locations)
StatusRecruiting
StartedAugust 6, 2026
Main results expectedDecember 31, 2026
Study endsFebruary 28, 2027
Registry record updatedAugust 21, 2026
Trial IDNCT07708545 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years and older with endoscopically confirmed bleeding peptic ulcers eligible for 14 days of tegoprazan or lansoprazole therapy.

Probably not a fit

Patients not showing ulcer healing or who have non-peptic causes of bleeding may not benefit from this comparison.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 randomized trial compares tegoprazan to lansoprazole for healing bleeding peptic ulcers. Eligible adults with upper GI bleeding receive initial stabilization, high-dose acid suppression, and gastroscopy with possible endoscopic therapy, followed by daily dosing of either tegoprazan or lansoprazole for 14 days. The primary goal is to determine which drug achieves better ulcer healing after two weeks. Endpoints include endoscopic healing at 14 days and safety in this patient population. Study sites include hospitals in Jakarta, Tangerang, and Padang under Universitas Indonesia leadership.

Why it matters

Potential benefit: If tegoprazan proves superior, patients may experience faster ulcer healing and reduced risk of rebleeding.

How similar studies have gone: Direct head-to-head comparisons of tegoprazan and lansoprazole are limited, making this study relatively novel in the bleeding peptic ulcer setting.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Subjects aged 18 years and over.
* Subjects with upper gastrointestinal bleeding caused by peptic ulcers diagnosed by gastroscopy.
* Willing to participate in the entire clinical study process, including:

  1. . Fluid resuscitation and blood transfusion, if necessary,
  2. . High-dose PPI therapy for 72 hours,
  3. . Gastroscopy within 24 hours of hospital admission and endoscopic hemostatic therapy, if necessary,
  4. . Lansoprazole 30 mg or tegoprazan 50 mg therapy for 14 days,
  5. . Treatment for H. pylori infection if positive,
  6. . Repeat gastroscopy after 14 days of treatment to assess the progress of therapy.

Exclusion Criteria:

* Subjects with a history of allergy to tegoprazan or lansoprazole
* Subjects with a history of allergy to tegoprazan or lansoprazole.
* Subjects with ulcers caused by gastric or duodenal cancer.
* Subjects with comorbidities such as chronic kidney disease stage 3 or higher and decompensated liver cirrhosis.
* Patients who are heavy alcohol drinkers and have used chemotherapy drugs, bisphosphonates, or potassium supplements in the past 2 weeks.

Where it's running

  • RSUD Balaraja
    Tangerang, Banten, Indonesia
    Recruiting
  • RSUPN Dr. Cipto Mangunkusumo
    Jakarta Pusat, DKI Jakarta, Indonesia
    Recruiting
  • RSUP Dr. M. Djamil
    Padang, West Sumatra, Indonesia
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.